Pages

Wednesday, July 18, 2012

Stock News 2012: Cityland unveils Pines Peak residential condo in Mandaluyong

Mandaluyong cityMandaluyong city (Photo credit: Wikipedia)
Cityland Development Corp. (CDL), a member of the Cityland Group of Companies, has unveiled its newest project, the 27-story medium-sized residential condominium Pines Peak, in Mandaluyong City.

In a disclosure to the Philippine Stock Exchange, CDC said Pines Peak, which will rise along the corner of Union and Pines streets in Mandaluyong, is targeted towards the fast-paced Filipino family.

Pines Peak will have more than 1,000 units with sizes ranging from 16 square meters to 40 square meters. Each floor may house 50 units.

A studio unit may sell for around P1.2 million while one-bedroom units may be priced at around P1.5 million each. Two-bedroom units may be sold at P2.1 million to P3.1 million each.

Amenities include a swimming pool, multi-purpose function room with movable playset, viewing deck and 24/7 security.

CDC said friendly and flexible payment terms are available to interested buyers. Special discounts will also be given for the early buyers during the project’s launch.

The Cityland Group is a trusted name in the real estate industry given its track record of developing condominiums. It has been in the real property development business for over 25 years.

Aside from CDC, the group has two other units – City and Land Developers (CLD) and Cityland Developers.

CDC was formed in 1978 to engage in the development of land for residential, office, commercial, institutional and industrial uses. The company’s projects include medium to high-rise offices, commercial and residential condominiums located in Makati, Mandaluyong and Ortigas in Pasig, and farmlots in Bulacan and Cavite. – Zinnia dela Peña

CLD, on the other hand, caters to the low-to-middle income segments since its projects are offered at affordable prices. It developed residential units in Paranaque as well as an office and residential condominium project in Ortigas Center.


Enhanced by Zemanta

No comments:

Post a Comment